Fig. 3

The KM survival curve shows the increased event in ESKD progression in crude (A), and the propensity score matches the (B) model. ESKD end-stage kidney disease, CKD chronic kidney disease, PPI proton pump inhibitor, H2RAs histamine-2 receptor antagonists.